Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma

Learn more about:
Related Clinical Trial
Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma RB Liquid Biopsy Biorepository Topotecan and Melphalan for Retinoblastoma Effect of Anesthetic Drugs on Neurocognitive Function in Children With Retinoblastoma Requiring Multiple Anesthetic Exposure – Preliminary Study Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome Nitroglycerin for Intra-arterial Chemotherapy in Pediatric Retinoblastoma. Autonomic Reflexes During Intra-arterial Chemotherapy for Retinoblastoma Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma Photodynamic Therapy With Visudyne for Human Retinoblastoma: A Preliminary Study Topotecan Episcleral Plaque for Treatment of Retinoblastoma G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment PCI Imaging System in Pediatric Ophthalmology Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma Determining Whether Multiple Anesthesia Exposures Affect Cognitive Function for Retinoblastoma Patients Conservative Treatments of Retinoblastoma Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma Intra-arterial Chemotherapy for Advanced Intraocular Retinoblastoma Photoscreening for Retinoblastoma RCT of Ballon Technique VS Selective Ophthalmic Artery Infusion For the Retinoblastoma Patients Studying Health Outcomes After Treatment in Patients With Retinoblastoma Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers A Study of the Effectiveness of a Local Injection of Chemotherapy for Retinoblastoma Intra-arterial Chemotherapy for Retinoblastoma Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in Advanced Intraocular Stage Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma Phase I Trial of Periocular Topotecan in Retinoblastoma Episcleral Topotecan for Treatment of Group D Retinoblastoma Can Pretreatment MRI be Used to Predict Intra-arterial Chemotherapy Response in Retinoblastoma? CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma Chemotherapy With or Without Radiation Therapy or Observation in Treating Young Patients With Advanced Retinoblastoma Who Have Undergone Surgery to Remove the Eye Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With Retinoblastoma Intravitreal Carboplatin for the Treatment of Participants With Recurrent or Refractory Intraocular Retinoblastoma Superselective Intra-arterial Chemotherapy Treatment for Retinoblastoma- 5 Year Results From Turkey Intra-arterial Chemotherapy(Chemosurgery) for Retinoblastoma Adjuvant Chemotherapy for High-risk Retinoblastoma After Enucleation Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma Chemotherapy in Treating Patients With Retinoblastoma New Strategies to Detect Cancers in Carriers of Mutations in RB1 Pilot Study of Topotecan/Vincristine With Subconjunctival Carboplatin for Patients With Bilateral Retinoblastoma Carboplatin Plus Vincristine in Treating Children With Retinoblastoma Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma Proton Beam Radiation Therapy for Intraocular and Periocular Retinoblastoma Quality of Life in Children Cured of Retinoblastoma Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009) Cardio-respiratory Events During Ophthalmic Artery Chemotherapy for Retinoblastoma Under a Deep Anesthesia Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma SPT Screening in Irradiated Hereditary Retinoblastoma Survivors Attention to Retinoblastoma Diagnosed in the Trauma Setting Carboplatin Periocular Injection for Retinoblastoma Morphological Analysis of the Pineal Gland in Pediatric Retinoblastoma Patients Using Magnetic Resonance Imaging Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From Guatemala Research on the Environment and Children’s Health: Retinoblastoma Intravitreal Injections of Melphalan for Retinoblastoma Efficacy Study of Lucentis in the Treatment of Retinoblastoma Feasibility of Generating Pluripotent Stem Cells From Patients With Familial Retinoblastoma A Study of Intra-Ophthalmic Artery Topotecan Infusion for the Treatment of Retinoblastoma Retinoblastoma Survivor Study: Assessment of General Health and Quality of Life Retinoblastoma Biomarker Study Cancer Biology of Retinoblastoma Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma Intra-arterial Chemotherapy for Children With Retinoblastoma Molecular Analysis of Retinoblastoma

Brief Title

Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma

Official Title

A Pilot Study Evaluating the Safety of Alternating Systemic Chemotherapy and Intra-Arterial Melphalan Chemotherapy in Children With Newly Diagnosed Advanced Intra-Ocular Retinoblastoma

Brief Summary

      The purpose of this study is to test the safety of the treatment combination of alternating
      standard chemotherapy and another (melphalan) chemotherapy at different interval schedules.
      Researchers want to find out what effects, good and/or bad, the treatment combination has on
      the patients and their retinoblastoma.
    


Study Phase

Phase 1

Study Type

Interventional


Primary Outcome

Adverse Event evaluation for newly diagnosed advanced retinoblastoma treated with melphalan therapy and systemic chemotherapy

Secondary Outcome

 Response rates after IAM combined with systemic CEV in patients with newly diagnosed advanced intraocular retinoblastoma

Condition

Advanced Intra-Ocular Retinoblastoma

Intervention

Melphalan

Study Arms / Comparison Groups

 Cohort 1
Description:  Patients will receive alternating treatments beginning with systemic chemotherapy then followed by intra-arterial (IA) therapy.
Bilateral retinoblastoma patients will be in Cohort 1.
For bilateral Bilateral retinoblastoma patients where one eye is stage A or B and the other eye is C, D, or E, only the higher stage eye (C, D, E) will be treated with IA chemotherapy unless the stage A or B eye is not amenable or has failed local therapy.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

6

Start Date

July 23, 2014

Completion Date

May 25, 2019

Primary Completion Date

May 25, 2019

Eligibility Criteria

        Inclusion Criteria:

          -  Age greater than or equal to 3 months up to 18 years.

          -  Intraocular retinoblastoma not previously treated with systemic chemotherapy,
             radiation therapy, or IA therapy. Local retinal therapy such as laser photocoagulation
             and cryotherapy will be permitted.

          -  Unilateral or bilateral retinoblastoma (RB) patients are eligible

          -  Patients will be registered on study based on the local exam under anesthesia (EUA)
             done for diagnostic purposes prior to study entry. The EUA done at study entry should
             be done within 14 days prior to study entry

          -  Patients may have had enucleation of one eye, as long as the remaining eye meets the
             eligibility criteria

          -  Involved eye(s) must meet the definition for International Classification of
             Retinoblastoma

          -  For unilateral retinoblastoma (see Appendix 1 for International Classification of
             Retinoblastoma):

               1. Group A eye that has failed local therapy

               2. Group B eye that has failed local therapy

               3. Group C eye that has failed local therapy

               4. Group D eye

               5. Group E eye that is not buphthalmic, is not planned for enucleation after first
                  cycle of chemotherapy, and is in a child less than 1 year of age

          -  For bilateral retinoblastoma (see Appendix 1 for International Classification of
             Retinoblastoma):

               1. Group A and Group A eyes that have failed local therapy

               2. Group A and Group B eyes that have failed local therapy

               3. Group A and Group C eyes

               4. Group A and Group D eyes

               5. Group A and Group E eyes in which the Group E eye is not planned for enucleation
                  after first cycle of chemotherapy

               6. Group B and Group B eyes that have failed local therapy

               7. Group B and Group C eyes

               8. Group B and Group D eyes

               9. Group B and Group E eyes in which the Group E eye is not planned for enucleation
                  after first cycle of chemotherapy

              10. Group C and Group C eyes

              11. Group C and Group D eyes

              12. Group C and Group E eyes even if early enucleation is planned for the Group E
                  eye.

              13. Group D and Group D eyes

              14. Group D and Group E eyes even if early enucleation is planned for the Group E
                  eye.

              15. Group E and Group E eyes if at least one eye is not planned for enucleation.

          -  Adequate Renal Function defined as: creatinine clearance or radioisotope Glomerular
             filtration rate (GFR) ³ 70 milliliter (mL)/min/1.73 m2 OR a serum creatinine based on
             age and gender derived from the Schwartz formula for estimating GFR (Schwartz et al.
             J. Peds, 106:522, 1985) utilizing child length and stature data published by the
             Center for Disease Control (CDC).

          -  Adequate hematological function defined as:

               1. Absolute Neutrophil Count > 1000/microliter

               2. Platelet Count > 100,000/microliter

          -  Adequate liver function defined as total bilirubin should be less than or equal to 1.5
             x upper limit of normal (ULN) for age and serum glutamic-oxaloacetic transaminase
             (SGOT) / aspartate aminotransferase (AST) and serum glutamic-pyruvic transaminase
             (SGPT)

             / alanine aminotransferase (ALT) < 5 x upper limit of normal (ULN) for age

          -  Adequate coagulation system as defined as an international normalized ratio (INR) of
             less than 1.4 and a partial thromboplastin time (PTT) of less than 34

          -  Women and men of child-bearing potential must agree to use adequate contraception such
             as hormonal or barrier method of birth control or abstinence prior to study entry and
             for the duration of study participation. Should the subject or the subject's partner
             become pregnant or suspect pregnancy while on protocol therapy, the treating physician
             must be informed immediately.

        Exclusion Criteria:

          -  Any evidence of extraocular retinoblastoma clinically or by magnetic resonance imaging
             (MRI) of brain and orbits with and without gadolinium. MRI may be done within 21 days
             prior to study entry.

             1. Evidence of systemic metastases on bilateral bone marrow, lumbar puncture, bone
             scan (or Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) scan), and/or any
             other additional tests done at study entry.

          -  Patients who have previously been treated with chemotherapy (with the exception of
             second inclusion criteria) radiation therapy, or intra-arterial therapy.

          -  Eyes with tumors that are amenable to local therapy with laser or cryotherapy without
             threat to vision

          -  Any technical factor that would prohibit use of catheterization of the ophthalmic
             artery (e.g., small for age infant, untreatable allergy to contrast).

          -  Abnormal cerebral vasculature noted on MR angiography that would increase the risk of
             the procedure, including but not limited to an incomplete Circle of Willis. Other
             abnormalities that are less severe than an incomplete Circle of Willis will be
             reviewed by the study chair in consultation with a neuro-interventional radiologist.

          -  Any serious ongoing condition, such as an untreated infection or organ dysfunction.

          -  Patients receiving any medications or substances that are inhibitors or inducers of
             CYP450 enzyme(s) are ineligible.

          -  Pregnant women are excluded from this study due to potential for teratogenic or
             abortifacient effects of therapy. Because there is an unknown but potential risk for
             adverse events in nursing infants secondary to treatment of the mother breastfeeding
             should be discontinued upon start of protocol therapy.
      

Gender

All

Ages

3 Months - 18 Years

Accepts Healthy Volunteers

No

Contacts

Anuradha Banerjee, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT02116959

Organization ID

13087

Secondary IDs

NCI-2015-01749

Responsible Party

Sponsor

Study Sponsor

University of California, San Francisco


Study Sponsor

Anuradha Banerjee, MD, Principal Investigator, University of California, San Francisco


Verification Date

April 2020